Thomas B. Cueni is Director General of IFPMA since 1 February 2017. Prior to joining IFPMA he was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland. For many years Thomas Cueni has been involved in the work of the European Federation of Pharmaceutical Industries and Associations, EFPIA, where he most recently served as Vice-Chair of the European Markets Committee and association representative on the Board. He represented the industry on the EU High Level Pharmaceutical Forum, was Chairman of EFPIA’s Economic and Social Policy Committee and Chairman of the EFPIA Task Force on the EU Commission’s Pharmaceutical Sector Inquiry. Thomas Cueni also represented Interpharma, which he successfully transformed from the association of Swiss Rx companies to the association of pharmaceutical research companies in Switzerland, on the Council of IFPMA. Prior to his appointment with Interpharma, Thomas Cueni had a career as a journalist, inter alia as London correspondent for the “Basler Zeitung” and “Der Bund”, and he served as a Swiss career diplomat with postings in Paris (OECD) and Vienna (IAEA, UNIDO). He studied at the University of Basle, the London School of Economics, and the Geneva Graduate Institute for International Studies, and has Master degrees in economics (University of Basel) and politics (London School of Economics, LSE).
@ThomasCueni

Sukaina has been reporting on all aspects of the pharmaceutical and biotechnology space since 2000. In her role as News Editor, SCRIP & Pink Sheet Moderator, she is tasked with ensuring Scrip Intelligence continues to provide the business critical information that its subscribers rely on. Sukaina’s prior positions include Editor of the newsletter BioVenture View and the magazine BioPeople. She has a PhD in biochemistry and molecular biology from University College London. Based in the UK, Sukaina is often asked to appear on TV and radio to commentate on business and R&D strategy related to the industry.
@Scripsuki

Tania Cernuschi works on access to vaccine supply at the Expanded Programme on Immunization (EPI) in WHO, Geneva. In this role, she leads various initiatives related to price transparency, shortages, supply for humanitarian emergencies. Tania also worked on broader related issues such as the development of a partner-shared Middle Income Countries (MICs) Strategy, support to Gavi transitioning countries, and IPV introduction in non-Gavi countries. Prior to WHO, Tania worked at the GAVI Secretariat as Senior Manager for the New Vaccines Programme working on development and launch of the Advanced Market Commitment (AMC) for pneumococcal vaccines, as well as the Rotavirus, IPV, HPV, JE, Cholera programmes. Tania has fourteen year experience working in design and management of development programmes in health and related fields in both headquarters and field with UN agencies (UNDESA, UNICEF), the Italian Government, and NGOs. Tania holds a MSc in Development Management from the London School of Economics & Political Sciences and an MPH from the London School of Hygiene and Tropical Medicine.

Luc Besançon is the Chief Executive Officer (CEO) at the International Pharmaceutical Federation (FIP) which is the global federation gathering 139 national associations of pharmacists and pharmaceutical scientists. Luc completed his Doctorat d’État en Pharmacie (PharmD) in 2004 further to an education in France (Université de Bourgogne) and Canada (Université Laval). He also completed a Master’s Degree in Communication (major in European Public Relations) at Paris V – La Sorbonne in 2003.
In 2008, Luc moved to the Netherlands to join FIP as a lead in Professional and Scientific Affairs. Prior to this, he had spent five years working as a Pharmaceutical and International Affairs advisor at the Ordre National des Pharmaciens, the French body in charge of pharmacist regulation.
@besanconluc and @FIP_org ‏

Ann Egede Ottosen – Ann leads the Polio Unit at UNICEF Supply Division and is responsible for the procurement of vaccines including OPV, IPV and Polio Stockpile in line with UNICEF’s accountabilities under the Global Polio Eradication Initiative. Prior to engaging in polio, Ann was responsible for the procurement of New Vaccines – pentavalent, pneumococcal and rotavirus vaccines – including supply planning for and supporting countries to introduce new vaccines in a sustainable manner. Since she joined UNICEF she was involved in the conceptual development of the Advance Market Commitment for pneumococcal vaccines, which ensured early access for Gavi supported countries at much reduced prices. Ann joined UNICEF in 2007 from a post as director of global vaccines sales and procurement after 12 years with a public vaccine manufacturer.

Anders Vinther is the Chief Quality Officer at Sanofi Pasteur, accountable for cGMP and quality performance globally for Sanofi Pasteur vaccines. Prior to working for Sanofi Pasteur Anders was VP of Quality at Roche and Genentech, and prior to that he was the co-founder of CMC Biologics, a contract manufacturing organization. Anders is actively involved in topics related to quality leadership and improved availability of vaccines globally.
@AnVinther